eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2018
vol. 35
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens

Danuta Nowicka, Joanna Maj, Alina Jankowska-Konsur, Anita Hryncewicz-Gwóźdź

Adv Dermatol Allergol 2018; XXXV (6): 577-581
Online publish date: 2018/08/13
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Alopecia areata (AA) is a skin disease of unclear etiology. In AA, topical immunotherapy with diphenylcyclopropenone (DPCP) is considered the most effective treatment; however, the most common therapies give unsatisfactory results.

Aim
To assess the efficacy of a topical application of a solution of DPCP based on the intensity, duration and number of exacerbations of AA and to compare the efficacy of two treatment regimens.

Material and Methods
In this prospective study, 39 patients with AA were enrolled. Group A was treated at weekly intervals and group B at 3-week intervals. Hair loss was assessed by independent dermatologists and documented by photography and dermoscopy.

Results
After 6 months’ therapy, hair regrowth greater than 50% was observed in 21 patients, while worsening, no regrowth, or regrowth of less than 50% was seen in 18 patients. Regrowth exceeding 50% of initial loss was observed in 12 of 17 patients with baseline hair loss < 50%, in 9 of 22 patients with severe alopecia, and in 4 of 9 patients with alopecia totalis. Both groups showed significant improvement with higher efficacy in group B (54%) than group A (46%).

Conclusions
Treatment at longer intervals may be safer and more comfortable for patients; however, further research is required.

keywords:

alopecia areata, diphenylcyclopropenone, topical, immunotherapy, prospective study

references:
Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 2006; 55: 438-41.
Tan E, Tay YK, Goh CL, Chin GY. The pattern and profile of alopecia areata in Singapore: a study of 219 Asians. Int J Dermatol 2002; 41: 748-53.
De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD. Juvenile versus maturity-onset alopecia areata: a comparative retrospective clinical study. Clin Exp Dermatol 1989; 14: 429-33.
Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ 2010; 341: c3671.
Brzezińska-Wcisło LA, Wcisło-Dziadecka D. Hair diseases: a big problem on a small surface. Postep Dermatol Alergol 2016; 33: 317-22.
Spano F, Donovan JC. Alopecia areata: part 2: treatment. Can Fam Physician 2015; 61: 757-61.
Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines. Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440-7.
Singh G, Lavanya M. Topical immunotherapy in alopecia areata. Int J Trichology 2010; 2: 36-9.
Happle R. Diphencyprone for the treatment of alopecia areata: more data and new aspects. Arch Dermatol 2002; 138: 112-3.
Marhaba R, Vitacolonna M, Hildebrand D, et al. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol 2007; 179: 5071-81.
Herbst V, Zoller M, Kissling S, et al. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 2006; 16: 537-42.
Ghersetich I, Campanile G, Lotti T. Alopecia areata: immunohistochemistry and ultrastructure of infiltrate and identification of adhesion molecule receptors. Int J Dermatol 1996; 35: 28-33.
Zoller M, Freyschmidt-Paul P, Vitacolonna M, et al. Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata. Clin Exp Immunol 2004; 135: 398-408.
Rodriguez TA, Fernandes KE, Dresser KL, Duvic M. Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol 2010; 62: 525-7.
Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466: 113-7.
Anderson I. Alopecia areata: a clinical study. Br Med J 1950; 2: 1250-2.
Wygledowska-Kania M, Bogdanowski T. Examination of the significance of psychological factors in the etiology of alopecia areata. I. Examining type A behavior. Przegl Lek 1995; 52: 311-4.
Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol 2005; 5: 6.
Nilforoushzadeh MA, Keshtmand G, Jaffary F, Kheirkhah A. Diphencyprone induced vitiligo: a case report. Case Rep Med 2012; 2012: 356236.
Pires MC, Martins JM, Montealegre F, Gatti FR. Vitiligo after diphencyprone for alopecia areata. Dermatol Res Pract 2010; 2010: 171265.
Ohlmeier MC, Traupe H, Luger TA, Böhm M. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata – a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol 2012; 26: 503-7.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe